Shandong Buchang Pharmaceuticals updates drug manufacturing license, expands production

Shandong Buchang Pharmaceuticals Company Limited (SSE:603858) has received approval from the Shandong Provincial Drug Administration for changes to its Drug Manufacturing License. The updates focus on entrusted and entrusted manufacturing arrangements, while other license details remain unchanged. The license is valid until May 25, 2030, covering production at multiple locations in Heze City, Shandong Province.

The changes include adding manufacturing for Ibuprofen Sustained Release Capsules, entrusted by Shandong Danhong Pharmaceutical Co., Ltd. Concurrently, the production scope for Angong Niuhuang Pills, previously manufactured for Liaoning Hancaotang Traditional Chinese Medicine Co., Ltd., has been reduced. Additionally, the production site at No. 1566 Huaxi West Road, Heze City, has been approved for entrusted manufacturing of Midanaxin tablets (0.1mg) for Shandong Buchang Shenzhou Pharmaceutical Co., Ltd., with this entrusted production valid until September 9, 2028.

These adjustments are expected to optimize the company's production structure and maintain stable manufacturing capacity, meeting market demand and positively impacting future operations.